How to Monitor PTSD Psychotherapy Outcomes by Major Depressive Disorder Status
How should clinicians monitor completion and PTSD outcomes in veterans receiving interpersonal psychotherapy or prolonged exposure when current MDD status is known?
Once PTSD psychotherapy has started, clinicians need concrete benchmarks for whether treatment is being completed and whether PTSD symptoms are improving. This guide applies to veterans treated with IPT or PE and uses the article's completion and outcome definitions to frame monitoring.
-
Track whether the patient reaches the minimum treatment dose
Use attendance of at least 8 sessions as the threshold for treatment completion. In the study, fewer than 8 sessions defined minimum-dose noncompletion, while both treatments were planned as 12 sessions with earlier completion allowed if participant and therapist judged improvement sufficient.
-
Monitor PTSD severity with CAPS-5 over treatment and follow-up
Assess PTSD symptom severity using the CAPS-5 at baseline, end of treatment, and at 3- and 6-month follow-ups. The study used CAPS-5 symptom severity as the primary PTSD outcome and also examined longitudinal change over these time points.
-
Classify categorical PTSD outcomes with the study thresholds
Define response as a decrease of 10 or more points in CAPS-5 symptom severity. Define loss of diagnosis as response plus no longer meeting diagnostic criteria for PTSD and a severity score below 25, and define remission as loss of diagnosis plus a severity score below 12.
-
Interpret PE progress more cautiously when MDD is present
In PE, veterans with MDD improved significantly less on CAPS-5 symptom severity than those without MDD and were significantly less likely to achieve loss of PTSD diagnosis and remission. When a patient in PE has current MDD, use this as a marker that PTSD improvement may be less robust even if treatment is continued.
-
Interpret IPT outcomes without assuming MDD-related attenuation
Within IPT, veterans with and without MDD did not differ in treatment noncompletion or PTSD symptom outcomes. If a patient in IPT has current MDD, the article does not support expecting poorer PTSD improvement on the basis of MDD status alone.
-
Use treatment retention as a separate signal from symptom response
Retention and symptomatic improvement did not move in the same direction across all subgroups. In this sample, PE had worse overall retention than IPT, with 52.9% versus 22.4% completing fewer than 8 sessions, and among those without MDD noncompletion was 63% in PE versus 18% in IPT.
Clinical Considerations
- High noncompletion rates in PE, especially 63% among those without MDD, may complicate interpretation of outcome differences because completers may have been selectively more likely to improve.
- The longitudinal mixed model found time, but not the interaction terms, to be statistically significant, and the authors emphasized limited power for subgroup analyses.
- Definitions of treatment noncompletion and depression vary across studies, which limits comparisons beyond this trial.
Bottom Line
Monitor at least 8-session completion and CAPS-5 outcome thresholds systematically, and interpret poorer PTSD improvement in PE patients with current MDD as a clinically relevant risk pattern not seen in IPT.
